| Name | Title | Contact Details |
|---|---|---|
Dominique Bridon |
Chief Technology Officer | Profile |
Start-up spirit. Experienced leadership. A mission of change. Ichnos (`īk-nōz) Sciences—a name taken from an ancient Greek word for “footprint”—is shifting how the world thinks about innovation in medicine. With a new approach to the research, discovery, and development of breakthrough therapies in oncology, we`re forging a new path forward. We aim to treat disease holistically, seeking to provide curative therapies that extend human life and improve quality of life. Science SHIFTED…from now on. Headquartered in the NYC metro area with additional teams in Switzerland, ours is a mission rooted in purpose and aimed at progress. Ichnos Sciences is fast-paced, forward-looking and visionary—a company where science, creativity, and a diversity of ideas thrive. We move quickly and nimbly, working together, challenging and supporting one another and ourselves to go further, look deeper, take scientific risks, shift perspectives, and drive forward the scientific advances that will leave an imprint on the world around us. At Ichnos Sciences, we dare to imagine a world where cure is possible. And we invite you to join us. Because cure is possible.
Geno is harnessing biology to remake everyday products and materials built by and for the planet. In response to the urgent climate crisis, Geno is developing and scaling sustainable materials derived from plant- or waste-based feedstocks instead of fossil fuels. Geno`s technology, built over the last 20 years, now drives materials and ingredients in applications ranging from cosmetics, carpets, to home cleaners, apparel and more.
J Morrison Group is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Strang Cancer Prevention Institute is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Korro Bio is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and common diseases. The company`s proprietary and modular platform, OPERA™ (Oligonucleotide promoted editing of RNA), builds on a deep understanding of ADAR biology, and combines data-driven design, oligo discovery and chemistry with clinically validated delivery vehicles, to achieve highly selective RNA editing. This unique technology enables the development of RNA editing therapeutics that deliver the functional benefits of gene therapy with a reversible, transient, titratable and specific treatment regimen, offering the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is based in Cambridge, Mass.